Skip to content
Screener

Charles River Laboratories CRL Impairment Charges

Impairment Charges at other companies

NeoGenomics logo
NeoGenomicsNEO
$0-100%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.77B+74.2%
Enterprise value$15.57B+56.4%
P/S3.2×+1.4×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-6%—
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%—
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemSix Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Net income (loss)$(15,562)$78,571
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization134,441239,871
Long-lived asset impairments26,27931,203
Stock-based compensation42,16230,184
Deferred income taxes12,077(41,030)
Write down of inventories3,16511,067
(Gains) losses and impairments on venture capital and strategic equity investments, net(6,936)12,899

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's impairment charges?
Charles River Laboratories (CRL) reported impairment charges of $10.42M in Q2 2026.
How has Charles River Laboratories's impairment charges changed year-over-year?
Charles River Laboratories's impairment charges decreased by 49.5% year-over-year, from $20.63M to $10.42M.
What is the long-term trend for Charles River Laboratories's impairment charges?
Over 2 years (2023 to 2025), Charles River Laboratories's impairment charges has grown at a 148.6% compound annual growth rate (CAGR), from $41.92M to $259.08M.
What does impairment charges mean?
Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.

Ask your AI about Charles River Laboratories's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude